78 related articles for article (PubMed ID: 1960868)
1. [HMG-CoA reductase inhibitors].
Endo A
Nihon Rinsho; 1991 Sep; 49(9):2004-9. PubMed ID: 1960868
[No Abstract] [Full Text] [Related]
2. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
[TBL] [Abstract][Full Text] [Related]
3. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Carmena R
Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
[No Abstract] [Full Text] [Related]
4. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin.
De Vries AC; Vermeer MA; Bredman JJ; Bär PR; Cohen LH
Exp Eye Res; 1993 Apr; 56(4):393-9. PubMed ID: 8500554
[TBL] [Abstract][Full Text] [Related]
5. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
Richter WO; Jacob BG; Schwandt P
Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
[TBL] [Abstract][Full Text] [Related]
7. Regulation of early cholesterol biosynthesis in rat liver: effects of sterols, bile acids, lovastatin, and BM 15.766 on 3-hydroxy-3-methylglutaryl coenzyme A synthase and acetoacetyl coenzyme A thiolase activities.
Honda A; Salen G; Nguyen LB; Xu G; Tint GS; Batta AK; Shefer S
Hepatology; 1998 Jan; 27(1):154-9. PubMed ID: 9425931
[TBL] [Abstract][Full Text] [Related]
8. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
Sirtori CR
Pharmacol Ther; 1993 Dec; 60(3):431-59. PubMed ID: 8073070
[TBL] [Abstract][Full Text] [Related]
9. The beneficial effects of HMG-coenzyme A reductase inhibitor in the primary and secondary prevention of atherosclerosis in the coronaries.
Drown DJ
Prog Cardiovasc Nurs; 1996; 11(2):38-9. PubMed ID: 8718962
[No Abstract] [Full Text] [Related]
10. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry.
Morris MJ; Gilbert JD; Hsieh JY; Matuszewski BK; Ramjit HG; Bayne WF
Biol Mass Spectrom; 1993 Jan; 22(1):1-8. PubMed ID: 8431499
[TBL] [Abstract][Full Text] [Related]
11. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones.
Ide H; Fujiya S; Aanuma Y; Agishi Y
Clin Ther; 1990; 12(5):410-20. PubMed ID: 2268863
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
[TBL] [Abstract][Full Text] [Related]
13. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering.
Hughes AD
J Hum Hypertens; 1996 Jun; 10(6):387-90. PubMed ID: 8872802
[TBL] [Abstract][Full Text] [Related]
14. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
Branchi A; Rovellini A; Fiorenza AM; Sommariva D
Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
[TBL] [Abstract][Full Text] [Related]
15. Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
al Rayyes O; Wallmark A; Florén CH
Hepatology; 1997 Apr; 25(4):991-4. PubMed ID: 9096609
[TBL] [Abstract][Full Text] [Related]
16. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
[TBL] [Abstract][Full Text] [Related]
17. Statins do more than just lower cholesterol.
Vaughan CJ; Murphy MB; Buckley BM
Lancet; 1996 Oct; 348(9034):1079-82. PubMed ID: 8874463
[No Abstract] [Full Text] [Related]
18. Inhibition of rat brain prostaglandin D synthase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Islam F; Watanabe Y; Hayaishi O
Biochem Int; 1990 Nov; 22(4):601-5. PubMed ID: 2127671
[TBL] [Abstract][Full Text] [Related]
19. [Extended worldwide experience. HMG-CoA reductase inhibitors: lovastatin and simvastatin].
Mantell G
Therapie; 1992; 47(2):161-4. PubMed ID: 1412144
[TBL] [Abstract][Full Text] [Related]
20. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase.
Endo A
J Med Chem; 1985 Apr; 28(4):401-5. PubMed ID: 3981532
[No Abstract] [Full Text] [Related]
[Next] [New Search]
